AI in cancer diagnosis market projected to grow to USD 2456 million by 2032 with 11% CAGR.

From GlobeNewswire: 2025-01-23 08:05:00

The AI in Cancer Diagnosis Market was valued at USD 960.1 million in 2023, projected to reach USD 2456.0 million by 2032 with a CAGR of 11.0%. Technological advancements in AI are driving growth, with key players like Intel, GE Healthcare, and Microsoft leading the market. Breast cancer dominates revenue, with hospitals as the primary end user, showcasing a strong potential for AI integration in cancer care services. North America leads the market, but Asia Pacific is expected to experience the highest CAGR due to rising cancer prevalence and adoption of digitalization in diagnostic labs. Recent developments include NVIDIA’s partnership with Deepcell and PathAI’s expansion of its PathExplore platform. GE Healthcare partners with the National Cancer Centre Singapore to enhance cancer care with AI. In 2023, breast, prostate, and lung cancer were most common in North America and Asia Pacific, with the U.S. seeing 297,790 new cases of breast cancer. AI adoption in cancer diagnosis is growing rapidly in these regions, with North America leading in healthcare spending on oncology. Hospitals in North America are integrating AI solutions for cancer diagnosis, with examples like FDA-approved AI systems for breast cancer and AI-based prostate biopsy analysis. The AI in Cancer Diagnosis market analysis & outlook report for 2024-2032 provides insights on adoption rates, user demographics, cost analysis, regulatory compliance, and more. SNS Insider offers market research and consulting services globally, providing clients with accurate data and insights to make informed decisions in evolving markets.



Read more at GlobeNewswire: AI in Cancer Diagnosis Market Size to Hit USD 2456 Million